Cardiovascular risk factor screening and management of obese patients at an outpatient pediatric cardiology center

Margaret Greco1, Arun Sood2, Soyang Kwon3

  • 1Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E. Chicago Ave., Box 21, Chicago, IL 60611-2605 USA ; Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL USA.

Springerplus
|November 9, 2016
PubMed

Insights

Pediatric cardiologists infrequently document all cardiovascular risk factors in obese children. Comprehensive assessment and obesity intervention documentation were similar across heart disease risk groups, suggesting a need for improved care coordination.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Health
  • Obesity Management

Background:

  • Obesity in children is a growing concern, increasing the risk of cardiovascular disease.
  • Pediatric cardiologists manage complex cases, including those with existing heart conditions and obesity.

Purpose of the Study:

  • To evaluate the documentation of cardiovascular risk factors and obesity management in obese children by pediatric cardiologists.
  • To compare the documentation rates across different heart disease risk categories.

Main Methods:

  • A retrospective review of medical records for obese children (≥95th BMI percentile) aged 2-17 years seen in pediatric cardiology outpatient clinics.
  • Data collected included assessment of seven cardiovascular risk factors and obesity management strategies.
  • Multivariable logistic regression analyzed physician documentation of obesity intervention by risk group.

Main Results:

  • Of 730 subjects, 16% had heart disease with increased atherosclerosis risk, 41% with average risk, and 43% no heart disease.
  • Documentation was highest for physical inactivity (53%) and obesity recognition (47%); other factors were less documented.
  • Obesity intervention was documented in 62% of records, with no significant difference between risk groups.

Conclusions:

  • Complete assessment of cardiovascular risk factors in obese pediatric patients is suboptimal.
  • The extent of risk factor assessment and obesity intervention documentation was similar among patients with varying degrees of heart disease risk.
  • Enhanced care coordination between pediatric cardiologists and primary care providers is recommended for uniform, comprehensive cardiovascular risk assessment.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
556
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
342